Rucaparib or Physician's Choice in Metastatic Prostate Cancer

ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy

Rucaparib Extends Progression-Free Survival in Selected Patients With Metastatic Castration-Resistant Prostate Cancer - The ASCO Post

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer

𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 on X: ⚡️ Just RELEASED NEJM: Ph 3 trial Rucaparib mCRPC patients w/BRCA1, BRCA2, ATM after 2nd gen ARPI. ✓62 mo rPFS 11.2 mo vs 6.4 mo(Ruc vs

Guidelines for Management of treating Rucaparib

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

NEJMστο X: Original Article: Rucaparib or Physician's Choice in Metastatic Prostate Cancer (TRITON3) #GU23 #oncology / X

Rucaparib or Physician's Choice in Metastatic Prostate Cancer

TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC

Advances in the treatment of metastatic prostate cancer: Trends in Cancer

Prostate cancer

PARP Inhibitors - Effective in Men with BRCA-Mutant Prostate Cancer - CancerConnect

Rucaparib or physician's choice in metastatic prostate cancer - UROONCO Prostate Cancer

Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors - ScienceDirect

Rucaparib or physician's choice in metastatic prostate cancer -ORCA